IMMB Stock Overview

Develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. More details

IMMB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($57K)

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Immunotech Laboratories, Inc. Competitors

Innovation Pharmaceuticals

OTCPK:IPIX

US$528.0

Histogen

OTCPK:HSTO.Q

US$122.6k

Vaxxinity

OTCPK:VAXX

US$12.7k

NexImmune

OTCPK:NEXI

US$154.8k

Price History & Performance

Summary of share price highs, lows and changes for Immunotech Laboratories
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.0001
Beta	0
1 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	0%
Change since IPO	-99.97%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	IMMB	US Biotechs	US Market
7D	0%	-4.8%	-0.5%
1Y	n/a	-3.2%	21.1%

Return vs Industry: Insufficient data to determine how IMMB performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how IMMB performed against the US Market.

Price Volatility

Is IMMB's price volatile compared to industry and market?
IMMB volatility
IMMB Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.3%
Market Average Movement	5.9%
10% most volatile stocks in US Market	18.2%
10% least volatile stocks in US Market	3.0%

Stable Share Price: IMMB's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IMMB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	www.immunotechlab.com

Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California.

Immunotech Laboratories, Inc. Fundamentals Summary

How do Immunotech Laboratories's earnings and revenue compare to its market cap?
IMMB fundamental statistics
Market cap	US$57.50k
Earnings (TTM)	-US$977.57k
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is IMMB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMMB income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$977.57k
Earnings	-US$977.57k

Last Reported Earnings

Dec 31, 2009

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did IMMB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/12 04:35
End of Day Share Price	2024/12/17 00:00
Earnings	2009/12/31
Annual Earnings	2009/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunotech Laboratories, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.